65 results about "Primary motor neuron" patented technology

The invention belongs to the technical field of medical instruments, and particularly relates to a spinal epidural ventral side double-wing-shaped stimulation electrode and motion function reconstruction system, the spinal epidural ventral side double-wing-shaped stimulation electrode and motion function reconstruction system comprises two wing panels, each wing panel comprises a flexible substrate, the flexible substrate is provided with two bifurcated preset-curvature double-wing structures; the electrode contact array is integrated on the flexible polar plate through a bonding pad; according to the double-wing-shaped flexible substrate, through a double-wing structure with a preset curvature, after being unfolded under the driving of a nickel-titanium alloy framework, the double-wing-shaped flexible substrate accurately covers a spinal cord ventral side and double-side anterior angle motor neuron pool, and the problem that a traditional single-piece / rod-shaped electrode can only cover a back side sensing area and cannot cover a back side sensing area is solved. The ventral motor neuron group cannot be directly activated; a stimulation target spot is transferred to a ventral functional core area from a dorsal non-target area for the first time, and the anatomical suitability bottleneck of motor function reconstruction is solved.

The present invention relates to a system and method configured for analysing acoustic parameters of speech to detect, diagnose, predict and / or monitor progression of a condition, disorder, or disease, and more particularly, any of paediatric and adult neurological and central nervous system conditions including but not limited to low back pain, multiple sclerosis, stroke, seizures, Alzheimer's disease, Parkinson's disease, dementia, motor neuron disease, muscular atrophy, acquired brain injury, cancers involving neurological deficits, paediatric developmental conditions and rare genetic disorders such as spinal muscular atrophy. The system and method extracts a first formant data set from words spoken by an individual and uses these to classify the vowels in the words on a first computing device, such as a mobile smart phone equipped with a microphone into which an individual speaks. The system stores at least some of these frequencies for the vowel formants in a second formant data set as a recorded file and provides the second formant data set as input to acoustic metrics to generate score data from which an assessment is made to determine the articulation level of the vowels in the words spoken by the individual, allowing allow for detection, diagnosis, prediction and / or monitoring progression of the condition, disorder, or disease.

Provided is a medicament for treating a disease related to motor neuron injury. The medicament comprises: a circular RNA having a circBank ID of hsa_circPTPRN2_018, and a proper diagnosis module and a drug carrier. Also provided is use of a circular RNA in preparing a medicament for diagnosing and treating a disease related to motor neuron injury.

In a method for inducing differentiation into neuromuscular junctions according to the present disclosure, the neuromuscular junctions are induced by: preculturing human pluripotent stem cells in a medium containing activin, bFGF, a WNT signal inhibitor, a BMP signal inhibitor, and a ROCK signal inhibitor; then culturing the stem cells in a medium containing bFGF, a ROCK signal inhibitor, a WNT signal activator, and a TGFβ signal inhibitor to differentiate into neuromesodermal cells; culturing the neuromesodermal cells in a medium containing a BMP signal inhibitor, a TGFβ signal inhibitor, a retinoic acid activator, and an SHH signal activator to differentiate into skeletal muscle progenitor cells and spinal motor neuron progenitor cells in the same culture dish; and culturing these progenitor cells in a medium for cell maturation containing BDNF, GDNF, AA, and dbcAMP.

The invention discloses an analysis method for storage of single vesicles in ventral spinal cord motor neuron-like organs induced and differentiated by an iPSC technology. The method sequentially comprises the steps of construction of an acetylcholine nano microelectrode sensor interface, recovery and culture of human pluripotent stem cells, directional differentiation of spinal cord movement organs and storage and detection of single vesicle acetylcholine. A new thought and a new method are provided for monitoring the level of acetylcholine stored in the single vesicles at the single cell level, and the method has important theoretical significance and wide practical value in research of pathogenesis of diseases, drug screening and the like in the field of neuroscience.

The present invention relates to sulphate salts of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine and pharmaceutically acceptable solvates thereof, for use in the treatment and / or prevention of motor neuron diseases and neuromuscular junction disorders.

The present invention relates to splice variants of the CERT1 protein that act as biomarkers for TDP-43 pathology, particularly motor neuron diseases such as amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD), as well as other neurological diseases such as Alzheimer's disease. In particular, the present invention relates to a method for identifying splice variants of CERT1 comprising cryptic peptide sequences, as well as related methods for identifying TDP-43 pathology and / or TDP-43 dysfunction in a subject, and a method for predicting the likelihood of successful treatment. Antibodies that bind to CERT1 splice variants and kits comprising said antibodies are also claimed.

It was discovered herein that neither the nuclear localization signal (NLS) nor the prion-like domain (PLD) of TDP-43 are required for in vitro embryonic stem cell culture and differentiation into motor neurons. ES cells expressing these TDP-43 mutants and differentiated into motor neurons that exhibit an ALS-like phenotype, from which the TDP-43 mutants redistribute to and accumulate in the cytoplasm, and the inability to regulate cryptic exon splicing, such that these cells can serve as a model for TDP-43 proteinopathies for testing candidate therapeutics that can dissipate such proteinopathies. In addition, these ES cells can be used to successfully generate non-human animals, e.g., mice, that also exhibit hallmark symptoms of ALS and can be used to test candidate agents useful for treating TDP-43 proteinopathies.

This application provides a novel differentiation factor for direct cross-differentiation from somatic cells to motor neurons, a composition containing the differentiation factor, a method for direct cross-differentiation using the composition, and uses for the novel differentiation factor. [Solution] A composition for direct cross-differentiation from somatic cells to induced motor neurons, the composition comprising (A) the Gsta4 protein or nucleic acid coding therefor; and (B) one or more proteins selected from Ascl1, Brn2, Myt1L, Hb9, ISL1, Lhx3, Ngn2 and NeuroD1 or nucleic acid coding therefor; and further comprising a viral capsid for transmitting (A) or (B).

1. Name of the product in this design: Walking Assistive Rehabilitation Device. 2. Purpose of this design: It is used in a walking rehabilitation device, which is a wearable functional neurostimulation instrument used for lower limb rehabilitation and recovery of muscles damaged by motor neurons. 3. The key design feature of this product is its shape. 4. The image or photograph that best illustrates the design's key points: 3D view 1. 5. Other circumstances requiring explanation: The human lower limb model is a supporting element and is not part of the content for which protection is sought.

A device includes a first unit for skeletal muscle tissue formation; a second unit for motor neuron culture; a third unit for causing the first and second units to communicate with each other; and a pillar serving as a scaffold for skeletal muscle tissue formation. The first unit includes a first base material and a first culture tank formed in the first base material. The second unit includes a second base material and a second culture tank formed in the second base material. The third unit includes a third base material and an axon channel formed in the third base material, through which a bundle of axons passes. One end of the third unit is connectable to the second unit and cause the axon channel and the second culture tank to communicate with each other. A first opening part is formed to the other end of the third unit.

The invention relates to the technical field of medical instruments, in particular to an anatomical adaptive spinal cord and waist expansion epidural abdominal side electrode which comprises an electrode body, a plurality of contacts are arranged on the electrode body, an electrical stimulation generating device is connected to the outside of the electrode body, and the electrode body is configured to be implanted into the epidural abdominal side of a human spinal cord and waist expansion area. The electrode is directly implanted into the outer ventral side of the spinal epidural to stimulate the spinal motor neurons in a targeted manner, so that the problem of energy shunt of dorsal indirect stimulation is avoided, target neurons are effectively activated under low stimulation intensity, and side effects such as stabbing pain and numbness of a patient are reduced.

Presented herein are methods of identifying a subject who has, or is at risk of developing a motor neuron disease, specifically Amyotrophic Lateral Sclerosis (ALS), and / or Primary Lateral Sclerosis (PLS), that includes determining a presence or amount of two or more micro-RNAs (miRNAs) selected from miR-199a-3p, miR-4454, miR-10b-5p, miR-151a-5p, miR-199a-5p, miR-151a-3p, miR-146a-5p, and / or miR-29b-3p in a subject's circulating blood, without determining a presence or amount of the miRNAs from neural-derived exosomes. Also presented herein are methods of preventing, treating, or delaying the onset of a motor neuron disease, specifically ALS and / or PLS.

The present disclosure provides methods of treatment of neurodegenerative disease, such as a motor neuron disease, in subjects in need thereof. A therapeutically effective dose of a suitable mast cell stabilizer may be administered to suitable subjects, wherein the suitability of a subject is determined by the rate of progression of the disease over time or by the severity of the disease. A therapeutically effective dose of a suitable mast cell stabilizer may be administered to suitable subjects, wherein the suitability of a subject is determined by subject genotype and / or family genotypes or medical history. In certain embodiments, the therapy may comprise a cromolyn homolog salt, and suitable subjects are persons with amyotrophic lateral sclerosis (ALS). In certain embodiments, the subjects are patients with slow progressing ALS and / or the subjects have mild to moderate ALS. In certain embodiments, the subjects are persons with sporadic ALS or persons without familial ALS.

This invention describes artificial expression constructs for regulating gene expression in target types of central nervous system cells. By using the artificial expression constructs of this disclosure, it is possible to express or modify the expression of synthetic genes in spinal motor neurons, including SpP1 spinal motor neurons, Parg spinal motor neurons, Ogdh1 spinal motor neurons, and ChAT spinal motor neurons; α motor neurons, including Chodl spinal motor neurons; γ motor neurons; spinal excitatory motor neurons, including Mafa excitatory neurons, Esrrg Trhr excitatory neurons, and Slc17a6 spinal excitatory neurons; spinal inhibitory neurons, including Slc6a5 spinal inhibitory neurons; whole spinal neurons, including Esrrg spinal motor neurons and types of neurons found throughout the spinal cord; cerebrospinal fluid contact neurons, including Poln spinal motor neurons; and non-neuronal cells of the spinal cord, including astrocytes and oligodendrocytes.

The application discloses a kind of construction methods and applications of motor neuron MNX1 reporter cell lines, belong to gene editing and stem cell technical field.The application develops a kind of expression motor neuron MNX1 reporter gene vector system by screening high-activity sgRNA, and vector system includes the guide vector of single-stranded guide RNA targeted to the vicinity of the termination codon of human motor neuron MNX1 gene, and the donor vector carrying the homologous arm in the vicinity of the termination codon of human motor neuron MNX1 gene.The application also includes the construction method of MNX1 reporter gene human pluripotent stem cell line into the above-mentioned vector system, the application can be applied to identify stem cell differentiation source human motor neuron, and the morphology and function of motor neuron are researched under the condition of living cell, provide important platform for the pathogenesis research of muscle-related disease, treatment method evaluation and new treatment target exploration.

The invention belongs to the technical field of nerve regulation and control, and relates to a 64-way nerve regulation and control system and method for directly targeting spinal cord motor neurons. The method comprises the steps that the low-power-consumption microprocessor configures a result through an operational analysis mode and then sends out a positive pulse trigger control signal and a negative pulse trigger control signal, and the 64-path positive / negative pulse trigger module selectively sends out positive / negative pulse stimulation signals according to the control signals; the 64-path positive / negative current and voltage feedback module samples the intensity of stimulation signals sent by the 64-path positive / negative pulse trigger module and sends the sampled signals back to the low-power-consumption microprocessor through an ADC0; and the low-power-consumption microprocessor starts current and voltage detection to analyze whether the current intensity meets the requirement or not. According to the method, 64 paths of electrodes can be randomly paired and cooperatively controlled, and frequency, current, voltage and pulse width parameters are controlled to be randomly adjustable in a set range, so that cooperative control on muscles and joints of lower limbs is realized, and paralyzed patients of different degrees can realize coordinated autonomous movement.

The invention provides arbutin-28beta-pyroglutamyl ester. The arbutin-28beta-pyroglutamyl ester is prepared by adopting a two-stage liquid fermentation process to culture a Circinella muscae CGMCC (China General Microbiological Culture Collection Center) 3.2695 strain. The arbutin-28beta-pyroglutamyl ester is a natural triterpenoid metabolite synthesized through microbial conversion for the first time, has good activity of promoting the growth of motor neurons, and can be used for preparing drugs for treating nervous system diseases.

The present application belongs to the technical field of nerve regulation, and relates to a 64-channel nerve regulation system and method for directly targeting spinal motor neurons. The method comprises the following steps: a low-power microprocessor analyzes and configures mode results through operation, and then sends out positive pulse trigger control signals and negative pulse trigger control signals; a 64-channel positive / negative pulse trigger module selectively sends out positive / negative pulse stimulation signals according to the control signals; a 64-channel positive / negative current voltage feedback module samples the stimulation signal intensity sent out by the 64-channel positive / negative pulse trigger module, and sends the sampling signals back to the low-power microprocessor through ADC0; and the low-power microprocessor enables current voltage detection, and analyzes whether the current intensity meets the requirements. The method can realize the arbitrary pairing and cooperative control of 64 electrodes, and the control frequency, current, voltage and pulse width parameters are all adjustable within the set range, so as to realize the cooperative control of lower limb muscles and joints, and make different degrees of paralyzed patients realize coordinated autonomous movement.

The invention relates to a DNA origami-based intracellular delivery platform for precisely targeting motor neurons, a DNA origami structure (BioDoori) comprises M13mp18 single-stranded DNA, biotin chains (biotin-DNA), fluorescent chains (fluorophore-DNA) and unmodified staple chains, each side of the DNA origami structure is loaded with 1-30 fluorescent chains and 1-10 biotin chains, and the biotin chains are loaded with 1-30 fluorescent groups and 1-10 fluorescent groups. The nucleotide sequence of the staple chain is as shown in SEQ ID NO: 1-208. According to the nano origami structure disclosed by the invention, accurate and efficient specific targeting aiming at motor neuron cells is realized, and lysosome escape efficacy of a DNA origami carrier is improved in a breakthrough manner.

An electromyography (EMG) strap and a wearable electronic device are provided. The EMG strap includes a flexible strap body; a flexible printed circuit board (FPCB), housed within the flexible strap body; a surface electromyography (sEMG) sensor assembly, disposed on the FPCB, where the sEMG sensor assembly is exposed from the flexible strap body and is configured to collect an EMG signal and pre-process the EMG signal to obtain a pre-processed analog signal; and a board-to-board (BTB) connector, disposed on the FPCB and electrically connected to the sEMG sensor assembly. The EMG strap can not only help in diagnosing conditions like muscular dystrophy and motor neuron disease but also play a pivotal role in developing advanced prosthetic devices that respond to muscle signals.

There is provided a method of promoting survival and / or function of an amyotrophic lateral sclerosis (ALS) or ALS-like motor, the method comprising contacting the motor neuron with an agent capable of reducing mitochondrial protein acetylation, particularly an agent selected from a deacetylase activator, such as nicotinamide (NAM) and 7-hydroxy-3-(4′-methoxyphenyl) coumarin (C12), or an acetyltransferase inhibitor, such as GCN5L1 siRNA of SEQ ID NO: 1. Also provided are related agents, oligonucleotides, uses and methods of identifying agents.

Described herein is the discovery that neither the nuclear localization signal (NLS) nor the prion-like domain (PLD) of TDP-43 is necessary for embryonic stem cell culture and differentiation into motor neurons in vitro. The ability of ES cells to express these TDP-43 mutants and differentiate into motor neurons that exhibit an ALS-like phenotype whereby the TDP-43 mutants redistribute to and aggregate in the cytoplasm and fail to regulate cryptic exon splicing allows these cells to act as a model of TDP-43 proteinopathy for the testing of candidate therapeutic agents that may resolve such proteinopathy. Additionally, these ES cells may be used to successfully generate non-human animals, e.g., mice, that also exhibit hallmark symptoms of ALS and that may be used in testing candidate agents useful in treating TDP-43 proteinopathies.

The invention relates to a motor neuron unit evaluation method and device, computer equipment, a computer readable storage medium and a computer program product. The method comprises the following steps: acquiring a first data set and a second data set; calculating a first index data set and a second index data set, corresponding to each candidate evaluation index, of each action potential data sample in the first data set and the second data set; performing difference test on the first index data set and the second index data set corresponding to each candidate evaluation index to obtain a difference test result; obtaining a target evaluation index corresponding to the target neuron evaluation type according to the candidate evaluation indexes of which the difference test results meet the index screening conditions; and calculating an index value corresponding to the target evaluation index according to the action potential measurement data of the to-be-evaluated object, and obtaining a motor neuron unit evaluation result of the to-be-evaluated object corresponding to the target neuron evaluation type according to the index value. By adopting the method, the pertinence of motor neuron unit evaluation can be improved.

The application discloses a kind of early motor neuron disease diagnostic methods, belong to medical auxiliary technical field, specifically include: receiving single task and limb rhythm double task under the condition of knocking voice signal sequence and facial infrared thermography video stream data, after time stamp alignment, division analysis section is according to pre-set vocalization unit, extract sound channel micro-disturbance fluctuation sequence and lip movement trajectory curve from each analysis section, carry out instantaneous phase synchronization analysis and obtain coupling stability parameter value, compare the coupling stability parameter value of two kinds of task conditions under the same vocalization grade, calculate stability attenuation ratio value, the attenuation ratio value of different vocalization grade is composed of attenuation feature vector, input pre-constructed attenuation feature discriminant space, output classification mark by pre-division area in discriminant space, the application is thus realized to the analysis and use of sound channel micro-disturbance and lip movement coupling stability attenuation feature under double task load.

The invention discloses application of S-adenosylhomocysteine in preparation of a medicine for treating neuromuscular diseases, and belongs to the technical field of medicines. The invention discloses a novel pharmaceutical application of S-adenosine homocysteine in preparation of drugs for treating neuromuscular diseases for the first time. Mechanism research finds that S-adenosylhomocysteine can enhance the ability of a Trmt61a / 6 compound to bind unmethylated tRNA and inhibit abnormal interaction between CMT2 pathogenic mutant protein and stress particle core protein, so that the ability of motor neurons to resist external stress is enhanced, and the S-adenosylhomocysteine has the effects of improving peripheral nerve and muscle lesions of neuromuscular diseases, improving the immunity of the motor neurons and improving the immunity of the motor neurons. And the potential of motor nerve dysfunction. The invention provides a direction for new clinical application of the S-adenosyl homocysteine. The invention provides possibility for preparing novel medicines for treating neuromuscular diseases.

The present invention relates to a composition comprising a c-AMP Response Element-Binding protein 3 (CREB3), in particular a variant of CREB3 protein, or a nucleic acid molecule encoding said CREB3 protein or said variant of CREB3 protein, for use as a medicament, in particular for treating or preventing diseases associated with a degeneration of motor neurons. The present invention further relates to CREB3 protein, in particular said variant of CREB3 protein, as a biomarker for the stratification or the prognosis of patients suffering, or susceptible of suffering, from a disease associated with a degeneration of motor neurons.

Use of a protein polymer in the treatment of amyotrophic lateral sclerosis. The protein polymer is obtained by stimulating and subsequently lysing mesenchymal stem cells, followed by isolation and purification. In SOD1 mutant mouse experiments, the protein polymer can significantly increase the number of motor neurons in the spinal anterior horn, ameliorate muscle atrophy, improve the motor ability of mice, and prolong the survival time of mice. In clinical trials, the protein polymer exhibits the effect of blocking the progression of amyotrophic lateral sclerosis, can reduce the concentration of TDP-43 protein in cerebrospinal fluid, and can increase the concentration of TDP-43 protein in serum.

Presented herein are methods of identifying a subject who has, or is at risk of developing a motor neuron disease, specifically Amyotrophic Lateral Sclerosis (ALS), and / or Primary Lateral Sclerosis (PLS), that includes determining a presence or amount of two or more micro-RNAs (miRNAs) selected from miR-199a-3p, miR-4454, miR-10b-5p, miR-151a-5p, miR-199a-5p, miR-151a-3p, miR-146a-5p, and / or miR-29b-3p in a subject's circulating blood, without determining a presence or amount of the miRNAs from neural-derived exosomes. Also presented herein are methods of preventing, treating, or delaying the onset of a motor neuron disease, specifically ALS and / or PLS.

The invention relates to a method for the automated optimization of sports training, wherein a portable non-invasive high-density electromyography sensor unit (1) is attached to a person (S1), the person performs a sports movement sequence to be optimized while wearing the sensor unit (1) (S2), data is recorded by the sensor unit (1) during the target movement sequence (S3), the data is evaluated by a computing unit (2) for information about active motor neurons (S4) and stored in a personal database (S5); and wherein, based on this, the computing unit (2) determines a training movement sequence (S6) that is different from the target movement sequence, but exhibits a minimal difference between the training movement sequence and the target movement sequence with respect to active motor neurons or muscle fibers activated by the motor neurons, according to a pre-stored muscle-building model.